Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.315 USD | +0.28% |
|
-5.53% | -41.89% |
12/06 | Cytek Biosciences to Seek M&A | CI |
12/06 | Transcript : Cytek Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-41.89% | 70Cr | D+ | ||
+5.16% | 21TCr | B | ||
+9.62% | 19TCr | B- | ||
+31.18% | 16TCr | B- | ||
+33.37% | 11TCr | A- | ||
+4.11% | 6.49TCr | A- | ||
+20.08% | 5.52TCr | B+ | ||
+1.51% | 4.91TCr | B+ | ||
-4.27% | 3.88TCr | A | ||
+0.88% | 3.56TCr | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CTKB Stock
- Ratings Cytek Biosciences, Inc.